Andrew F Adler
Overview
Explore the profile of Andrew F Adler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kirkeby A, Nelander J, Hoban D, Rogelius N, Bjartmarz H, Storm P, et al.
Cell Stem Cell
. 2023 Oct;
30(10):1299-1314.e9.
PMID: 37802036
Cell replacement therapies for Parkinson's disease (PD) based on transplantation of pluripotent stem cell-derived dopaminergic neurons are now entering clinical trials. Here, we present quality, safety, and efficacy data supporting...
2.
Alekseenko Z, Dias J, Adler A, Kozhevnikova M, van Lunteren J, Nolbrant S, et al.
Nat Commun
. 2022 Jun;
13(1):3046.
PMID: 35650213
Stem cell therapies for Parkinson's disease (PD) have entered first-in-human clinical trials using a set of technically related methods to produce mesencephalic dopamine (mDA) neurons from human pluripotent stem cells...
3.
Aldrin-Kirk P, Akerblom M, Cardoso T, Nolbrant S, Adler A, Liu X, et al.
Stem Cell Reports
. 2021 Dec;
17(1):159-172.
PMID: 34971563
Transplantation in Parkinson's disease using human embryonic stem cell (hESC)-derived dopaminergic (DA) neurons is a promising future treatment option. However, many of the mechanisms that govern their differentiation, maturation, and...
4.
Tiklova K, Nolbrant S, Fiorenzano A, Bjorklund A, Sharma Y, Heuer A, et al.
Nat Commun
. 2020 Jul;
11(1):3630.
PMID: 32669619
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
5.
Tiklova K, Nolbrant S, Fiorenzano A, Bjorklund A, Sharma Y, Heuer A, et al.
Nat Commun
. 2020 May;
11(1):2434.
PMID: 32415072
Cell replacement is a long-standing and realistic goal for the treatment of Parkinson's disease (PD). Cells for transplantation can be obtained from fetal brain tissue or from stem cells. However,...
6.
Adler A, Bjorklund A, Parmar M
Stem Cells
. 2020 Feb;
38(6):716-726.
PMID: 32101353
Fetal neural progenitor grafts have been evaluated in preclinical animal models of spinal cord injury and Parkinson's disease for decades, but the initial reliance on primary tissue as a cell...
7.
Adler A, Cardoso T, Nolbrant S, Mattsson B, Hoban D, Jarl U, et al.
Cell Rep
. 2019 Sep;
28(13):3462-3473.e5.
PMID: 31553914
Cell replacement is currently being explored as a therapeutic approach for neurodegenerative disease. Using stem cells as a source, transplantable progenitors can now be generated under conditions compliant with clinical...
8.
Kumamaru H, Kadoya K, Adler A, Takashima Y, Graham L, Coppola G, et al.
Nat Methods
. 2018 Aug;
15(9):723-731.
PMID: 30082899
Spinal cord neural stem cells (NSCs) have great potential to reconstitute damaged spinal neural circuitry, but they have yet to be generated in vitro. We now report the derivation of...
9.
Cardoso T, Adler A, Mattsson B, Hoban D, Nolbrant S, Wahlestedt J, et al.
J Comp Neurol
. 2018 Jul;
526(13):2133-2146.
PMID: 30007046
Dopamine (DA) neurons derived from human embryonic stem cells (hESCs) are a promising unlimited source of cells for cell replacement therapy in Parkinson's disease (PD). A number of studies have...
10.
Dulin J, Adler A, Kumamaru H, Poplawski G, Lee-Kubli C, Strobl H, et al.
Nat Commun
. 2018 Jan;
9(1):84.
PMID: 29311559
Neural progenitor cell (NPC) transplantation has high therapeutic potential in neurological disorders. Functional restoration may depend on the formation of reciprocal connections between host and graft. While it has been...